A New Patent Using Peptides

Posted on January 14, 2016 by LifeTein Peptide

A patent has been published that describes new methods of manipulating plant stomatal development through artificially controlling how CRSP is expressing in plant cells. The cleavage of epidermal patterning factor 2 (EPF2) by a serine protease CRSP is a key regulating mechanism in plant stomatal development. A 30-mer EPF2 peptide, dual-tagged with DABCYL and EDANS, was synthesized by LifeTein to evaluate the protease activity of synthetic CRSP in a FRET assay.

New Patent Using Peptides Synthesized By LifeTein

Compositions and methods for mediating plant stomatal development in response to carbon dioxide and applications for engineering drought tolerance in plants.

Peptide Synthesis Home Page

Our Services:

COVID-19 Services & Products

Custom Antibody Services

Rush Peptide Synthesis

Peptide Nucleic Acids (PNAs)

Custom Peptide Synthesis Services

Gene Synthesis Service

Custom Chemical Synthesis

Predicting type 1 diabetes in children

Posted on January 14, 2016 by LifeTein Peptide

MAP is a pathogenic bacterium infecting livestock and found prevalent in dairy products. Because some of its proteins are sequentially homologous to human zinc transporter 8 (ZnT8) protein and proinsulin (PI), children could develop autoimmunity against ZnT8 and PI after being exposed to MAP in dairy foods, and generating antibodies against MAP, and might subsequently develop type I diabetes. The hypothesis was tested by using ZnT8, PI and MAP peptides synthesized by LifeTein to assess the cross-reactivity of antibodies in sera samples from at-risk children.

Type 1 Diabetes in Children

Journal of Diabetes Research, Article ID 5842701, in press. Recognition of ZnT8, Proinsulin, and Homologous MAP Peptides in Sardinian Children at Risk of T1D Precedes Detection of Classical Islet Antibodies.

Peptide Synthesis Home Page

Our Services:

COVID-19 Services & Products

Custom Antibody Services

Rush Peptide Synthesis

Peptide Nucleic Acids (PNAs)

Custom Peptide Synthesis Services

Gene Synthesis Service

Custom Chemical Synthesis

Advancing Cancer Treatment with LifeTein’s Peptide Synthesis in Antibody Therapy

Posted on January 14, 2016 by LifeTein Peptide

LifeTein’s Role in Overcoming Cetuximab Resistance in Colorectal Cancer

In the ongoing battle against cancer, monoclonal antibody therapies have emerged as a beacon of hope. Cetuximab, a therapeutic monoclonal antibody, has been developed to halt tumor growth by targeting the extracellular domain of the Epidermal Growth Factor Receptor (EGFR) on cancer cells’ surfaces. However, the emergence of resistance to cetuximab in clinical settings has posed a significant challenge.

Researchers have made a breakthrough using peptides synthesized by LifeTein to address this critical issue. By incorporating methylated arginine residues into these peptides, scientists successfully generated specific antibodies in mice. This innovative approach led to the discovery that Arg198 and Arg200 of EGFR undergo methylation by protein arginine methyltransferase 1 (PRMT1) in colorectal cancer cells. This methylation is now understood to be a key factor in the development of resistance to cetuximab.

The findings, published in the Journal of Clinical Investigation (2015;125(12):4529-4543. doi:10.1172/JCI82826), highlight the potential of PRMT1-mediated methylation of the EGF receptor as a target for overcoming cetuximab resistance. This research paves the way for developing more effective treatments for cancer patients, marking a significant advancement in the field.

LifeTein’s Comprehensive Peptide Synthesis Services

LifeTein’s contribution to this groundbreaking research is part of their broader commitment to advancing scientific discovery through their peptide synthesis services. Their offerings include:

COVID-19 Services & Products: Addressing the urgent needs of the pandemic.
Custom Antibody Services: Tailored solutions for specific research needs.
Rush Peptide Synthesis: Accelerated synthesis for time-sensitive projects.
Peptide Nucleic Acids (PNAs): Offering versatility in genetic research.
Custom Peptide Synthesis Services: Expertise in synthesizing complex peptides.
Gene Synthesis Service: Advanced techniques for precise gene construction.
Custom Chemical Synthesis: Broadening the scope of molecular innovation.

Exploring Other Innovations by LifeTein

LifeTein is not just limited to cancer research. Their expertise in peptide synthesis has led to various other significant contributions in the biomedical field:

Nanoparticles Enhanced by Cell-Permeable Peptides: LifeTein’s peptides are instrumental in improving the delivery and efficacy of nanoparticles in therapeutic applications.
Predicting Type 1 Diabetes in Children: Leveraging peptide technology, LifeTein is at the forefront of developing predictive tools for early detection of type 1 diabetes in pediatric populations.
Targeting Peritoneal Carcinomatosis with iRGD Peptide: The tumor-permeable peptide iRGD, synthesized by LifeTein, is a promising agent in targeting peritoneal carcinomatosis, enhancing drug delivery to tumor sites.
Simplifying and Enhancing Biosensors: LifeTein’s peptides play a crucial role in developing simpler, more efficient biosensors, pushing the boundaries of diagnostic technology.
Innovative Patents Using Peptides: LifeTein’s cutting-edge research has led to new patents in peptide-based technologies, showcasing their commitment to innovation and scientific advancement.

LifeTein’s pivotal role in overcoming cetuximab resistance in colorectal cancer is a testament to its expertise in peptide synthesis and its applications in medical research. Their diverse range of services and contributions to various fields underscore their commitment to advancing scientific knowledge and developing solutions for pressing health challenges. As LifeTein continues to explore the frontiers of peptide synthesis, their work not only illuminates the path to better cancer treatments but also opens doors to new possibilities in biomedical research and therapeutics.

LifeTein Peptide Cited in Cell

Posted on November 18, 2014 by LifeTein Peptide

Peptide library is increasingly used to define antibody epitopes and substrate specificities of protein kinases. For epitope mapping, overlapping peptides are made to span the antigenic protein sequence. The antigenic determinant recognized by a monoclonal antibody can then be screened and defined. The alanine scanning method can also be used to assess that residue’s contribution to antibody binding and to determine which substitutions affect antibody recognition (mutational analysis). Unrelated synthetic peptides can be used to evaluate the antibody cross-reactivity.

Peptide by LifeTein Cited in Cell

Overlapping peptides from LifeTein were used to map the region of Fragment 3 by epitope mapping of anti-Fzd2 antibody. This anti-Fzd2 antibody was found to reduce tumor growth. Wnt signaling plays a critical role in colorectal cancer. Researchers found that Wnt receptor Frizzled2 (Fzd2) and its ligands Wnt5a/b are elevated in metastatic liver, lung, colon, and breast cancer cell lines. Their high level expression correlates with markers of epithelial-mesenchymal transition (EMT). By epitope mapping using synthetic peptides from LifeTein, the researchers mapped the epitope to a specific region. The antibody to Fzd2 was found to reduce cell migration and invasion. Targeting this pathway may provide a cure for patients with tumors expressing high amount of Fzd2 and Wnt5a/b. We have developed an antibody to Fzd2 that reduces cell migration and invasion and inhibits tumor growth and metastasis in xenografts. We propose that targeting this pathway could provide benefit for patients with tumors expressing high levels of Fzd2 and Wnt5a/b.

Cell, Volume 159, Issue 4, 6 November 2014, Pages 844–856, DOI: 10.1016/j.cell.2014.10.032 A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis

Peptide Synthesis Home Page

Our Services: COVID-19 Services & Products Custom Antibody Services Rush Peptide Synthesis Peptide Nucleic Acids (PNAs) Custom Peptide Synthesis Services Gene Synthesis Service Custom Chemical Synthesis Other Posts: Phospho-specific antibodies by LifeTein published in Nature Synthesis of multiple antigenic peptides: strategies and limitations The Structural Basis of Peptide-Protein Binding Strategies Synthetic Peptides Used for indirect ELISA

Phospho-specific antibodies by LifeTein published in Nature

Posted on October 18, 2013 by LifeTein Peptide

Jia Shen. et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497, 383–387 (16 May 2013), doi:10.1038/nature12080 LifeTein helped designed and synthesized a series of phosphorylated peptides. Then the peptides were used for phospho-specific antibody productions. The phospo-specific antibodies by LifeTein were confirmed to react with the epidermal growth factor receptor (EGFR). The Hung’s lab showed that AGO2-Y393 phosphorylation mediates EGFR-enhanced cell survival and invasiveness under hypoxia. These findings suggest that modulation of miRNA biogenesis is important for stress response in tumour cells. … The following peptides were chemically synthesized for antibody production in mice (Lifetein Conc.), Elisa verification (LifeteinConc.) and peptide competition assay in immunohistochemistry (IHC)… Supplementary information